Financial Information

Interim results for the six months ended 30 June 2024

26 September 2024

Arecor Therapeutics Annual Report and Accounts 2023

31 May 2024

Preliminary Results for The Year Ended 31 December 2023

16 May 2024

Interim results for the six months ended 30 June 2023

14 September 2023

Arecor Therapeutics Annual Report and Accounts 2022

4 May 2023

Unaudited Preliminary Results For The Year Ended 31 December 2022

20 April 2023

Interim results for the six months ended 30 June 2022

8 September 2022

Arecor Therapeutics Annual Report and Accounts 2021

27 April 2022

Final results for the year ended 31 December 2021

25 April 2022

Interim results for the six months ended 30 June 2021

23 September 2021

Investor Meet Company – Interim results for the six months ended 30 June 2024

3 October 2024

Proactive Investors interview – H1 highlights: GLP-1, AT278, and new partnerships

26 September 2024

Proactive Investors interview – Arecor CEO Presents Positive Phase I Trial Results of AT278 at EASD Conference

18 September 2024

Proactive Investors One2One Investor Forum

29 May 2024

AT278 Clinical Trial Results Update

21 May 2024

Proactive Investors interview – Arecor’s fast-acting insulin shows superior results in diabetes trial

21 May 2024

Preliminary Results for the year ended 31 December 2023

16 May 2024

Proactive Investors interview – Arecor Therapeutics reports strong 2023 results and outlines expanding product pipeline

16 May 2024

Proactive Investors interview – Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes and obesity treatment

13 March 2024

Proactive Investors interview – Arecor Therapeutics CEO highlights key 2023 business achievements and future milestones

2 February 2024

Proactive Investors interview – Arecor reveals deal with ‘global medical products company’

5 December 2023

Proactive Investors interview – Arecor Therapeutics takes major step with first commercial sale of AT220

17 November 2023

Investor Meet Company presentation – Interim Results for six months ended 30 June 2023

20 September 2023

Proactive Investors interview – Arecor Therapeutics expecting a busy end to the year after solid first half progress

15 September 2023

Interim results for the six months ended 30 June 2023

14 September 2023

Proactive Investors interview – Arecor Therapeutics gets second phase 1 trial for AT278 underway

24 May 2023

Investor Meet presentation – Preliminary Results For The Year Ended 31 December 2022

26 April 2023

Preliminary Results for the year ended 31 December 2022

20 April 2023

Proactive Investors interview – Arecor Therapeutics has “a strong basis to accelerate” growth strategy

20 April 2023

ShareSoc webinar

7 March 2023

Proactive Investors interview – Arecor Therapeutics “confident” in collaboration pipeline after another new deal

14 February 2023

Proactive Investors interview – Arecor Therapeutics “looking forward to another successful year”

19 January 2023

Proactive Investors interview – Arecor Therapeutics’ scientist hopeful that artificial pancreas “edging closer”

15 November 2022

Proactive Investors interview – Arecor’s study shows rapid-acting insulin could enable artificial pancreas system

12 October 2022

Proactive Investors interview – CEO talks through interims, clinical trials and growing momentum

9 September 2022

Proactive Investors interview – Tetris Pharma acquisition plans and focus on key product Ogluo

5 August 2022

Tetris Pharma Acquisition Investor Meet Company Presentation

4 August 2022

Arecor Proactive Investors Interview – Collaboration with global pharmaceutical company

20 June 2022

KOL Webinar on the Need for Concentrated and Rapid Acting Insulin

31 May 2022

Interim results for the six months ended 30 June 2021

23 September 2021

Trinity Delta – AT278 co-development deal in advanced discussions

4 February 2025

Trinity Delta – Tetris Pharma to be wound down; Ogluo rights returned

10 January 2025

Trinity Delta – New licence adds AT351 to partnered pipeline

6 January 2025

Trinity Delta – H124: Focus on next steps for diabetes and obesity

26 September 2024

Trinity Delta – EASD 2024 Positive Phase I for AT278 in Type II diabetes

17 September 2024

Trinity Delta – Funding growth; diabetes still the key value driver

23 July 2024

Trinity Delta – AT278 ultra-concentrated insulin superior to benchmarks

20 May 2024

Trinity Delta – FY23 results evidence broader revenue base

16 May 2024

Trinity Delta – Novel diabetes drug-device deal inked with Medtronic

9 May 2024

Trinity Delta – TRx co-development deal centred on oral GLP-1 product

13 March 2024

Trinity Delta – New deals & first royalties to aid growth; key data H124

1 February 2024

Trinity Delta – Sanofi deal for INBRX-101 validates Arestat technology

24 January 2024

Trinity Delta – Second In-House Specialty Hospital Deal

7 December 2023

Trinity Delta – Appreciating a well-executed development strategy

30 November 2023

Trinity Delta – AT220 European launch marks first Arestat success

17 November 2023

Trinity Delta – Growth plans starting to stack up

14 September 2023

Trinity Delta – Pipeline and partnership progress

20 July 2023

Trinity Delta – Continued delivery with key AT278 data due in Q423

20 April 2023

Trinity Delta – Hikma licence milestone achieved

13 January 2023

Trinity Delta – Getting the chemistry right

20 December 2022

TRINITY DELTA – SPECIALTY HOSPITAL PRODUCTS FORMULATION COLLABORATION

10 November 2022

Trinity Delta – AT247 Phase I pump data confirms promising profile

11 October 2022

Trinity Delta – Broadening opportunities and preparing for the future

21 September 2022

Trinity Delta – Key clinical diabetes events on track for H2 2022

8 September 2022

Trinity Delta – Arecor Therapeutics acquisition of Tetris Pharma and £6m equity raise

9 August 2022

Trinity Delta – AT278 hits the sweet spot

31 May 2022

Trinity Delta – Arecor Therapeutics: Ambitious, focussed, and delivering on its promise

25 April 2022

Arecor Trinity Delta – Formulation Expertise Exemplified in Diabetes

25 January 2022